ATE278398T1 - Verfahren zur behandlung von viralen infektionen - Google Patents

Verfahren zur behandlung von viralen infektionen

Info

Publication number
ATE278398T1
ATE278398T1 AT97923598T AT97923598T ATE278398T1 AT E278398 T1 ATE278398 T1 AT E278398T1 AT 97923598 T AT97923598 T AT 97923598T AT 97923598 T AT97923598 T AT 97923598T AT E278398 T1 ATE278398 T1 AT E278398T1
Authority
AT
Austria
Prior art keywords
protoporphyrin
infected
virus
cells
viral infections
Prior art date
Application number
AT97923598T
Other languages
English (en)
Inventor
Ehud Ben-Hur
Zvi Malik
Original Assignee
New York Blood Ct Inc
Univ Bar Ilan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Ct Inc, Univ Bar Ilan filed Critical New York Blood Ct Inc
Application granted granted Critical
Publication of ATE278398T1 publication Critical patent/ATE278398T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT97923598T 1996-05-08 1997-05-07 Verfahren zur behandlung von viralen infektionen ATE278398T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/646,548 US5895786A (en) 1996-05-08 1996-05-08 Method for treating viral infections
PCT/US1997/007811 WO1997041855A1 (en) 1996-05-08 1997-05-07 Method for treating viral infections

Publications (1)

Publication Number Publication Date
ATE278398T1 true ATE278398T1 (de) 2004-10-15

Family

ID=24593477

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97923598T ATE278398T1 (de) 1996-05-08 1997-05-07 Verfahren zur behandlung von viralen infektionen

Country Status (9)

Country Link
US (2) US5895786A (de)
EP (1) EP0904075B1 (de)
JP (1) JP2000510123A (de)
AT (1) ATE278398T1 (de)
AU (1) AU2936597A (de)
CA (1) CA2254070C (de)
DE (1) DE69731083T2 (de)
IL (1) IL126917A (de)
WO (1) WO1997041855A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3970492B2 (ja) * 1999-12-14 2007-09-05 コスモ石油株式会社 ピーリング用組成物
KR100365151B1 (ko) * 2000-05-08 2003-02-11 김형락 어류 병원성 세균과 바이러스의 감염 예방 및 치료를 위한δ-아미노레불린산의 신규한 용도
KR100373147B1 (ko) * 2000-05-10 2003-02-25 김형락 스쿠치카충 감염증의 치료제
US6409719B1 (en) 2000-09-18 2002-06-25 Don A. Manning Light stint implant device for treatment of long term viral infection
JP4754731B2 (ja) * 2001-07-31 2011-08-24 コスモ石油株式会社 豚成育促進剤及び豚成育促進方法
DE10162712A1 (de) * 2001-12-19 2003-07-17 Blutspendienst Der Landesverba Verfahren zur Inaktivierung von Bakterien und Leukozyten in Blut oder Blutprodukten
FR2857264A1 (fr) * 2003-07-09 2005-01-14 Maco Pharma Sa Procede d'inactivation photodynamique des pathogenes au moyen d'ala
US7311928B2 (en) * 2003-12-09 2007-12-25 Briant Burke Topical compositions containing tea tree oil for treatment of viral lesions
US20060020033A1 (en) * 2004-07-21 2006-01-26 Ali Moiin Method for treating dermatological viral infections
US7825153B2 (en) * 2004-08-16 2010-11-02 Ceramoptec Industries, Inc. Photosensitizer formulations and their use
EP1938801A1 (de) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
JP5574329B2 (ja) * 2010-05-06 2014-08-20 国立大学法人 岡山大学 ミトコンドリアの蛍光染色方法
AU2013291455B2 (en) * 2012-07-19 2016-07-21 Sbi Pharmaceuticals Co., Ltd. Prophylactic/therapeutic agent for influenza virus infection
GB201215675D0 (en) * 2012-09-03 2012-10-17 Univ Exeter Compound
WO2014203833A1 (ja) * 2013-06-19 2014-12-24 Sbiファーマ株式会社 プロトポルフィリンix生成促進用医薬組成物
CN107405323A (zh) * 2015-04-10 2017-11-28 思佰益药业股份有限公司 含有ala类的病毒感染症预防/治疗剂
TW202106293A (zh) * 2019-04-26 2021-02-16 日商日本紐翱醫藥股份有限公司 黃病毒(flavivirus)感染症治療劑
JP7497790B2 (ja) * 2019-12-27 2024-06-11 国立大学法人北海道大学 豚コレラの治療及び/又は予防剤
JP7058026B2 (ja) * 2020-04-22 2022-04-21 ネオファーマジャパン株式会社 新型コロナウイルス感染症(covid-19)の治療及び/又は予防剤
CN115916178A (zh) * 2020-07-15 2023-04-04 日本纽翱医药股份有限公司 非洲猪瘟(African Swine Fever:ASF)的治疗剂和/或预防剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120649A (en) * 1990-05-15 1992-06-09 New York Blood Center, Inc. Photodynamic inactivation of viruses in blood cell-containing compositions
DK0660712T3 (da) * 1992-09-21 2001-08-27 Quadra Logic Tech Inc Transcutation in vivo-aktivering af lysfølsomme midler i blod
WO1996028412A1 (en) * 1995-03-10 1996-09-19 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
GB0229604D0 (en) 2002-12-19 2003-01-22 Pursuit Dynamics Plc Improvements in or relating to pumping systems

Also Published As

Publication number Publication date
DE69731083D1 (de) 2004-11-11
JP2000510123A (ja) 2000-08-08
EP0904075A4 (de) 1999-12-22
WO1997041855A1 (en) 1997-11-13
CA2254070A1 (en) 1997-11-13
DE69731083T2 (de) 2005-09-08
EP0904075A1 (de) 1999-03-31
AU2936597A (en) 1997-11-26
CA2254070C (en) 2008-07-29
IL126917A0 (en) 1999-09-22
US6323012B1 (en) 2001-11-27
EP0904075B1 (de) 2004-10-06
IL126917A (en) 2001-11-25
US5895786A (en) 1999-04-20

Similar Documents

Publication Publication Date Title
DE69731083D1 (de) Verfahren zur behandlung von viralen infektionen
DE69535758D1 (de) Lipid-analoge zur behandlung von viralen infektionen
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
BRPI0213786B8 (pt) peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
ATE233738T1 (de) Kleine moleküle anwendbar in der behandlung von entzündgskrankheiten
TR199802441A3 (tr) Kanda asiri ürik asit bulunmasinin tedavisi ve önlenmesi için yöntem ve terkip.
NO953995D0 (no) Ionenolymere som anthelmintica i dyr
BR0111158A (pt) Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente
ATE190843T1 (de) Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
ATE201997T1 (de) Zusammensetzung und verfahren zur verstärkung von elektrotransport-wirkstoffzufuhr
DE69730214D1 (de) Zusammensetzung und verfahren zur behandlung von herpes simplex
ATE251631T1 (de) Dipohosphonsäuresalze für die behandlung von osteoporose
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DE69413637D1 (de) Verwendung von verzweigtkettigen Aminosäuren zur Herstellung eines Arzneimittels zur Behandlung von tardiver Dyskinesia
EA199800819A1 (ru) Способ лечения биполярного расстройства
ATE155795T1 (de) Verwendung von leukoregulin zur behandlung von mit einem envelope-virus infizierten tier
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
EA200100385A1 (ru) Композиция и способ лечения нарушения гемостаза у субъекта (варианты)
DE68908445D1 (de) Mittel zur behandlung von lebererkrankungen.
DE3585312D1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyrido(1,2-a)pyrimidin-3-carboxamid zur vorbeugung und behandlung von gastrointestinalschaeden.
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
DE69932741D1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties